Navigation Links
Contract Research Organization, WCCT Global, Welcomes Gary Urban as Executive Director, Corporate Compliance and Quality
Date:2/18/2013

Costa Mesa, California (PRWEB) February 18, 2013

WCCT Global, a contract research organization (CRO) supporting Phase I - IV biopharmaceutical and device development headquartered in Southern California, today welcomes Gary Urban as Executive Director, Corporate Compliance and Quality. As a Contract Research Organization professional for the past 16 years, Gary has held executive-level positions with global responsibility for Quality Management Systems, Clinical and Corporate Operations, and Information Technology. Gary earned a Bachelor of Science in Business Administration with a concentration in international business from Colorado Technical University. Gary is also certified in Good Clinical Practice and Lean Six Sigma Black Belt. When asked how Gary felt to be joining WCCT Global, he replied, “I am extremely excited to have joined this dynamic and growing organization, and look forward to leveraging my background in organizational optimization, leading companies successfully through growth and change, while ensuring the highest levels of quality, efficiency, and client and associate satisfaction.”
This is another great addition to WCCT Global because the service offering that WCCT Global is providing continues to grow which is why WCCT Global is contacted by sponsors all over the world to perform clinical studies in many different therapeutic areas. WCCT Global’s Chief Operating Officer Jon Rojas says, “Gary’s experience in I.T. and quality assurance allows WCCT Global to bring new technology, ensuring quality within our organization which in turn expands the breadth of services that we can offer to our clients.”
WCCT Global is a multi-site, full service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, “With compassion for people, we strive for tomorrow’s therapies to be available today” truly exemplifies the focus and reason for our cutting edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.
If you would like to request information about how WCCT Global can assist your organization with a clinical study, please CLICK HERE.

Read the full story at http://www.prweb.com/releases/2013/2/prweb10437942.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. PBM Experts to Discuss Non-Rate Contracting Terms in Feb. 25 Atlantic Information Services Webinar
2. MMS Group Explores New Opportunities for Placing Healthcare Contractors
3. EMR Staffing Partners Preparing for 25% Increase in Contract Staffing Business
4. Securityhunter, Inc. Selected as a Top 25 Baltimore Defense Contractor for the Baltimore Business Journal's 2013 Book of Lists
5. PLEXERA® LLC Launches Contract Research Services Business for Biomolecular Interaction Studies
6. NHS consultant contract fails to increase productivity
7. Care2Learn/Upstairs Solutions and Jarlette Health Services Sign Multi-Year Contract for Online Training and Record-Keeping
8. NIH awards Georgia malaria research consortium up to $19.4 million contract
9. Federal government renews contract for collecting and maintaining national stem cell transplantation database
10. BMC awarded contract to study validity of primary care drug screening tools
11. Collagenase for Dupuytrens contracture: Added benefit not proven
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... 13, 2016 , ... Valentine’s Day is nearly upon us, and most singles ... great outfit, flawless hair, and a sparkling personality are all well and good, but ... night at home with Rover. (Actually, man’s best friend might not even want to ...
(Date:2/13/2016)... ... February 13, 2016 , ... Many individuals looking to lead a healthy lifestyle ... reasons. IsoPasta by Isolator Fitness has delved into this niche allowing those giving ... high-carb repercussions. IsoPasta has 30 grams of protein and only 7 grams of ...
(Date:2/13/2016)... ... February 13, 2016 , ... The producers of Enterprises TV are ... The increasingly modern world of instantaneous consumption proves very convenient for businesses. With new ... oil and coal, which pollutes our air, water, and soil. It can also threaten ...
(Date:2/13/2016)... ... February 13, 2016 , ... Christie Medical Holdings, Inc. presented ... a VeinViewer® Vision vein finder for the nursing school simulation lab. ... and draw blood, combining technology with traditional technique. , “VeinViewer is a wonderful ...
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... In the ... forward. They’ll groom themselves to perfection, go out of their way to be romantic, ... – just take a look at any online dating profile. , A recent ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... and Company (NYSE: LLY ) today announced that the ... patent would not presently be infringed by Actavis marketing pemetrexed ... Italy and Spain ... --> --> In ... Lilly,s patent would be indirectly infringed by Actavis marketing certain ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis Pharmaceuticals, ... a $47.1 million Series D preferred stock ... Management, Hillhouse Capital Group and venBio Global ... Investments, AJU IB Investment, and Epidarex Capital. The ... to further advance clinical trials in the ...
(Date:2/11/2016)... , Feb. 11, 2016 The primary goal ... future adoption patterns on the usage of liquid biopsy. ... following: - Timeframe of liquid biopsy adoption ... cfDNA and Evs—by organization type - Sample inflow to ... blood, saliva, stool, serum, and so on. - Correlation ...
Breaking Medicine Technology: